Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/11473
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3384]
- IOC - Artigos de Periódicos [12488]
Metadata
Show full item record
T CELL ACTIVATION AND CYTOKINE PROFILE OF TUBERCULOSIS AND HIV-POSITIVE INDIVIDUALS DURING ANTITUBERCULOUS TREATMENT AND EFAVIRENZ-BASED REGIMENS
HIV-Positive Individuals
Antituberculous Treatment
Efavirenz-Based Regimens
Cytokine
T Cell Activation
HIV-TB patients
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Laboratório de Pesquisa Clínica em Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, Brasil.
Abstract
Introduction: The profile of immune activation markers in tuberculosis and HIV-infected patients is already known. The
impact of simultaneous infections on the immune parameters is still not fully explored.
Methods: We conducted a prospective study to estimate trajectories of activated T cell subsets and the profile of anti- and
pro-inflammatory cytokines in a group of HIV-TB individuals, previously naı¨ve for HAART, recruited from a randomized
clinical trial during TB treatment and first antiretroviral therapy with efavirenz. Patients were evaluated according to the
immunosuppression levels at baseline as group 1 (CD4,200 cells/mm3) and group 2 (CD4.200 cells/mm3). These
parameters were measured at the time of HAART initiation (started about 30 days after the onset of TB treatment) and at
the follow-up visits after 30, 60, 90 and 180 days. Trajectories were estimated using least squares estimates of the
coefficients of a restricted cubic spline function in time after adjusting for subject effects, bootstrapping it 500 times.
Results: Increase of CD4 T cell counts and suppression of HIV viral load were observed for all patients under HAART and TB
treatment. Descendent trajectories were observed for the activated CD8+/CD38+ and CD3+/HLA-DR+ T cell subsets, and for
plasma concentration of gamma- interferon (IFN-c). Except for TNF-a and IL-2 discrete variations were observed for the
other cytokines. Differences in the trajectories of these parameters were observed for groups 1 and 2. Higher values of IFN-c,
IL-2, IL-6 and IL-10 were observed for group 1 from the baseline to two months after treatment initiation, whereas reduced
levels of TNF-a were observed for this group between 60 and 120 days of HAART.
Conclusion: Independent of the immunosuppression profile at baseline, HIV-TB patients under HAART were able to recover
the CD4+ T cell counts, and control viral replication and immune activation parameters over time.
Keywords
TuberculosisHIV-Positive Individuals
Antituberculous Treatment
Efavirenz-Based Regimens
Cytokine
T Cell Activation
HIV-TB patients
Share